NEW YORK, AUGUST 10, 2020 (GLOBE NEWSWIRE) – iBio, Inc. (NYSE AMERICAN: IBIO) (“iBio” as the “Company”), a biotechnology corporation and biology contract organization, today released an update on one of its own vaccine candidates designed to prevent infection by the SARS CoV-2 virus. iBio explores a variety of adjuvants …
Read More »iBio Provides Update on IBIO-201 COVID-19 Vaccine Program NYSE: IBIO
